Take 2 capsules of the Estrogen Balance Formula daily with your last meal.

• Baseline: Complete Anxiety Levels and Body Composition Measurement assessments.
• Day 45: Body Composition Measurement.
• Ongoing: Safety & Adverse Event Check-ins.

The "30 Day Estrogen Balance Optimization Protocol" is a single-arm observational trial designed to investigate the efficacy of a new Estrogen Balance formula. This study aims to offer a biological solution for individuals struggling with persistent weight in the hips and thighs, a condition often resistant to conventional dietary approaches. The formula, created by Elwin Robinson and Dr. Miriam Mikicki, MD, targets hormone metabolism to address the "Gynoid" fat distribution pattern. Participants will take part in a 30-day trial to evaluate the formula's impact on their hormonal health, with the ultimate goal of validating this novel health paradigm.

In this "Signal Phase" study, participants will serve as their own controls, providing a preliminary indication of the formula's effectiveness. Participants will receive the Estrogen Balance Formula and tools to track their progress, emphasizing the importance of data collection. The study experience includes comprehensive baseline assessments such as anxiety levels, body composition measurements, and blood tests. Participants are instructed to take two capsules daily with their evening meal, while continuous data collection throughout the study will enable an objective evaluation of the formula's impact on their health.

The study's design aims to identify any positive signals indicating the formula's potential benefits. If successful, this trial will provide valuable safety data and pave the way for more robust study designs. Participants' diligent tracking and data contribution will help build evidence supporting the formula's efficacy, potentially influencing future medical approaches to targeted metabolic support. As a part of Efforia's Minimal Risk Umbrella protocol, this study is a critical step towards establishing a new standard for health interventions rooted in personalized data-driven insights. For more detailed information, please refer to the Minimal Risk Umbrella protocol.

As part of our submission for the IRB review of the "30 Day Estrogen Balance Optimization Protocol," we wish to clarify that the statistical plan for this study is designed to align with the Minimal Risk Umbrella protocol. This alignment ensures that our approach to data analysis remains consistent with the overarching guidelines and methodologies established within the umbrella, thereby maintaining the integrity and safety of the study.

The statistical analysis will focus on evaluating the changes in key outcome measures such as body composition, hormone levels, and anxiety scores over the 30-day period. These measures include hips circumference, estradiol levels, and GAD-7 scores, respectively. The baseline and outcome measurement points for each of these variables have been clearly defined to track progress and assess the effectiveness of the Estrogen Balance formula.

For reviewers who are interested in assessing the specifics of our statistical plan, we kindly refer you to the detailed statistical framework provided under the Minimal Risk Umbrella protocol. This comprehensive framework provides further insights into the methodologies to be applied, ensuring a robust evaluation of the study outcomes while adhering to minimal risk standards.

We appreciate your attention to this detail and are confident that our adherence to the umbrella protocol will facilitate a thorough and consistent review process. Thank you for considering our protocol submission.

In this study, which is conducted under the Minimal Risk Citizen Science Umbrella Protocol, we acknowledge the inherent limitations of a single-arm observational trial, particularly the absence of a control group, which may introduce bias into our results. This design choice is aligned with our broader objective to democratize clinical research, allowing us to explore research questions that might otherwise be overlooked due to resource constraints. To address potential bias, we have implemented an expectations questionnaire to quantify how participants' anticipations might influence the outcomes, providing us a clearer picture of the Estrogen Balance Formula's true impact on hormone balance and body composition over a 30-day period.

Our study design also carefully considers sample size and statistical methodologies, including the potential stratification by demographic variables, to further mitigate these biases. By doing so, we aim to enhance the interpretability of our findings despite the limitations associated with a single-arm trial. This approach allows us to derive meaningful insights into the efficacy of the Estrogen Balance Formula, leveraging the personalized data to empower participants with a tailored understanding of their hormonal and weight management journey. Moreover, the study is structured as a signal detection effort; should the results indicate a positive effect, they will inform the design of more robust, controlled trials that can further validate these initial findings.

Finally, as part of the Minimal Risk Umbrella Protocol, our study supports the overarching goal of Efforia to democratize clinical research, ensuring that important questions about hormone balance and weight management are pursued even with limited initial evidence. By providing individualized insights into the potential benefits and risks of the Estrogen Balance Formula, we enable participants to make informed health decisions. While this trial faces limitations typical of its design, it serves as a crucial first step in exploring the role of estrogen in weight management, with the potential to guide future, more comprehensive studies. For more details on the study design and its alignment with Efforia's mission, we encourage interested parties to refer to the Minimal Risk Umbrella Protocol.